Cal Matrix

Cal Matrix, licence 80069541: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Other names: Bone Builder Active, Bone Matrix 2.0, Cal Apatite Bone Builder Active
Licence holder: Metagenics Inc.
NPN or DIN-HM: 80069541
Status: Active licence
Licence date: 18 May 2016
Revision date: 20 May 2022
Form: Comprimé
Route of administration: Orale
Application type: Non traditionnelle

If this product were sold in France

Dose déclarée au-delà d'une limite
Chrome: up to 120 µg a day according to the dosing instructions published by Health Canada (3 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 25 µg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
Dose déclarée au-delà d'une limite
Vitamine C: up to 249 mg a day according to the dosing instructions published by Health Canada (3 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 180 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
Dose déclarée au-delà d'une limite
Vitamine D: up to 5.025 µg a day according to the dosing instructions published by Health Canada (3 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 5 µg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and source	Per dosage unit, according to the source	Maximum per day, adult
Phosphore Source : Durapatite	119.0 mg	357,000 µg
Phosphore Source : Phosphate de calcium, dibasique	119.0 mg	357,000 µg
Sulfate de 2-Amino-2-désoxy-D-glucose Source : Exosquelette de crabe	83.0 mg	Not calculated
Sulfate de 2-Amino-2-désoxy-D-glucose Source : Exosquelette de crevette	83.0 mg	Not calculated
Zinc Source : Citrate de zinc	2.5 mg	7,500 µg
Chrome Source : Citrate de chrome(III)	40.0 mcg	120 µg
Calcium Source : Durapatite	204.0 mg	612,000 µg
Vitamine C Source : Ascorbate de calcium	83.0 mg	249,000 µg
Vitamine C Source : Ascorbate de niacinamide	83.0 mg	249,000 µg
Vitamine C Source : Ascorbate de sodium	83.0 mg	249,000 µg
Vitamine C Source : Palmitate d'ascorbyle	83.0 mg	249,000 µg
Vitamine C Source : Ascorbate de potassium	83.0 mg	249,000 µg
Vitamine C Source : Acide ascorbique	83.0 mg	249,000 µg
Vitamine C Source : Ascorbate de magnésium	83.0 mg	249,000 µg
Magnésium Source : Bisglycinate de magnésium	37.0 mg	111,000 µg
Equisetum arvense Source : Sommité Extract : Matériel brut sec Extraction ratio : 4.0:1.0 Dry plant equivalent : 100.0 mg	25.0 mg	Not calculated
Equisetum arvense Source : Sommité	25.0 mg	Not calculated
Cuivre Source : Produit de chélation de cuivre (II) et de protéine végétale hydrolysée (PVH)	0.33 mg	990 µg
Manganèse Source : Citrate de manganèse (II)	0.16 mg	480 µg
Bore Source : Citrate de bore	65.0 mcg	Not calculated
Vitamine D Source : Cholécalciférol	1.675 mcg	5.025 µg
Niacinamide Source : Niacinamide	6.0 mg	Not calculated

Non-medicinal ingredients

Xylitol, Stéarate de magnésium, Croscarmellose de sodium, L-cystéine, Cellulose, NA, Hypromellose, D-ribose, L-Glutathione, Bioflavonoïdes d'agrumes, Pyrophosphate de tétrasodium, Dioxyde de silicium, L-Lysine, Hydroxypropylcellulose

Recommended doses in Canada

Population	Age	Quantity per serving	Frequency
Adultes	Not specified	3.0 Comprimé	1.0 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Adequate calcium as part of a healthy diet, may help prevent bone loss/osteoporosis. Helps in the development and maintenance of bones and teeth. Adequate calcium as part of a healthy diet may reduce the risk of developing osteoporosis. Helps the body to metabolize carbohydrates, fats and proteins. Helps to relieve joint pain associated with osteoarthritis. Helps to protect against the deterioration of cartilage. A factor in maintaning good cartilage and/or joint health . Helps in the absorption and use of calcium and phosphorus. Calcium intake, when combined with sufficient Vitamin D, a healthy diet and regular exercise may reduce the risk of developing osteoporosis. Helps to produce and repair connective tissue.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Précautions et mises en garde
Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. For adult use only. Take with food a few hours before or after taking other medications.

Source

Official Health Canada record, licence 80069541

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Has the product changed? Photograph the packaging.